According to a recent story by Reuters, Gilead Science Inc’s experimental antiviral drug remdesivir has demonstrated success in early clinical trials. Giliead has been in discussions with the FDA on how to fast track the drug for regulatory approval.
If approved, this will be the first time a treatment or preventive vaccine would be available as an FDA approved treatment fro COVID-19.
Gilead has gone on record earlier, that they are prepared to donate their existing supply to hospitals. They have 1.5 million doses in reserve, which could treat approximately 140,00 patients.
Remdesivir was previously tried as a possible treatment for Ebola but was found to be unsuccessful. Researchers believe that remdesivir’s ability to disable virus replication systems can prevent the virus from overwhelming the host’s immune system.